VERV - Verve Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
VERV price evolution
VERV
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $2.63 | $3.04 | $5.77 | $5.9 |
| Inventory | ||||
| Total current assets | $556.46 | $590.89 | $620.33 | $637.95 |
| Long term investments | ||||
| Property, plant & equipment | $99.55 | $101.93 | $104.55 | $107.8 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $663.91 | $700.91 | $732.36 | $752.69 |
| Current liabilities | ||||
| Accounts payable | $4.64 | $6.83 | $3.05 | $6.64 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $42.64 | $40.37 | $31.29 | $37.01 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $155.35 | $154.82 | $149.29 | $153.19 |
| Shareholders' equity | ||||
| Retained earnings | -$692.98 | -$642.85 | -$593.04 | -$544.3 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $5.9 | $1.01 | ||
| Inventory | ||||
| Total current assets | $637.95 | $563.16 | $367.13 | $73.97 |
| Long term investments | ||||
| Property, plant & equipment | $107.8 | $110.66 | $9.06 | $3.98 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $752.69 | $679.22 | $384.12 | $78.41 |
| Current liabilities | ||||
| Accounts payable | $6.64 | $2.42 | $7.08 | $0.04 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $37.01 | $35.09 | $22.02 | $7.32 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $153.19 | $128.29 | $26.77 | $17.16 |
| Shareholders' equity | ||||
| Retained earnings | -$544.3 | -$344.24 | -$186.85 | -$66.54 |
| Other shareholder equity | $357.35 | |||
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $6.87 | $6.69 | $5.7 | $5.14 |
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $63.77 | $65.53 | $62.54 | $59.09 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.1 | $0.07 | $0.11 | $0.03 |
| Interest expense | $6.89 | $7.43 | $8.14 | $6.34 |
| Net income | ||||
| Net income | -$50.13 | -$49.8 | -$48.74 | -$48.35 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $11.76 | $1.94 | ||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $234.88 | $167.63 | $87.07 | $40.63 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.28 | $0.05 | ||
| Interest expense | $23.17 | $6.87 | $0.14 | $0.16 |
| Net income | ||||
| Net income | -$200.07 | -$157.39 | -$120.31 | -$45.7 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $45.33 | -$11.48 | -$41.63 | $27.69 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $24.05 | $24.03 | $22.73 | $212.58 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$47.47 | -$64.69 | -$61.98 | $90.72 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $27.69 | -$155.96 | -$239.1 | -$51.13 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $212.58 | $328.96 | $377.09 | $92.63 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $90.72 | $50.67 | $60.11 | $6.23 |
News
Fundamentals
| Market cap | $306.39M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 84.64M |
| Revenue | $24.40M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$197.03M |
| Revenue Q/Q | 638.97% |
| Revenue Y/Y | N/A |
| P/E ratio | -1.56 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 12.56 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$2.33 |
|---|---|
| ROA | -27.65% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 13.05 |
| Quick ratio | N/A |